businessbriefs
11:07in productionCh. 1 · The Handshake/ 11:07 · ceiling 15 min
Startups & venture

Phil Knight

Nike began not with a shoe, but with a handshake and a regional distribution licence.

Nike's origin is a case study in low-capital, high-leverage commercial positioning: distribution rights, direct sales, and outsourced branding—not invention or infrastructure.

Startups & ventureBrandingStartupsRetailBranding across the network →
Chapters & takeaways6
  1. 1:40
    The Handshake

    Blue Ribbon Sports was founded on a handshake—not a business plan, patent, or prototype.

  2. 3:00
    The Licence

    Knight’s first move was identifying and licensing an existing product—not inventing one.

  3. 4:04
    The Green Plymouth Valiant

    Early sales happened from a car at track meets—not stores, websites, or ads.

  4. 5:35
    The $35 Logo

    The 'swoosh' was commissioned for $35—not developed in-house or priced as strategic IP.

  5. 6:50
    The Employee Suggestion

    The name 'Nike' was suggested by an employee—not coined by Knight or derived from mythology research.

  6. 8:06
    The 1969 Pivot

    Full-time commitment came only after four years of part-time sales—not from investor backing or early traction.

Worth your time?

Yes. Study the whole thing.

4/ 5
What works
  • distribution licensing
  • direct-to-customer sales
  • low-cost branding
What does not
  • product development
  • manufacturing
  • intellectual property creation
  • venture funding
Study it if
  • founders building from distribution
  • marketers studying logo economics
  • students of brand-as-asset
Skip it if
  • inventors
  • engineers
  • VC analysts
The written brief1 min read

What the company or idea is

Nike is a global sports footwear, equipment and apparel company co-founded by Phil Knight and Bill Bowerman in 1964 as Blue Ribbon Sports.

How it actually makes money

Nike makes money by selling branded sports footwear, equipment and apparel. Its early revenue came from distributing Japanese Tiger shoes in the western United States, then shifted to its own branded products after rebranding in 1971.

What works

Knight secured exclusive U.S. distribution rights for Tiger shoes in 1962, sold them directly at events, and renamed the business with a cheap, memorable logo—proving that brand identity can be outsourced, scaled, and monetised before product ownership.

What does not

The sources do not establish that Knight built Nike on athletic expertise, manufacturing capability, or intellectual property. There is no mention of R&D, patents, supply chain control, or vertical integration in the material.

What to take from it

The gap between narrative (the ‘swoosh’, the ‘green Plymouth Valiant’, the ‘handshake’) and mechanism (a regional distribution licence, a $35 logo, sales at track meets) is where the real leverage lies—not in mythmaking, but in low-cost, high-leverage commercial positioning.

Is it worth your time

Yes—if you are studying how a distribution deal, not product innovation or marketing theory, seeded a global brand; or how a $35 logo commission became a structural asset through scale and enforcement.

Same desk · Startups & venture4 of 47
10:40
Amgen1980Amgen’s origin story is unusually concrete: founded in 1980, public by 1983, two gene-cloning projects yielding two FDA-approved drugs by 1991. No vague mission statements — just molecules, milestones, and money raised to get there.
9:30
Marc AndreessenAndreessen Horowitz is a venture capital firm built on Marc Andreessen’s technical legacy and narrative authority — not on disclosed financial performance or repeatable investment mechanics.
10:34
Enphase Energy2006Enphase Energy is a hardware-first energy technology company that built market position by solving a specific, observable failure in residential solar—central inverter underperformance—then scaling through successive generations of microinverters. Its business model relies entirely on third-party installers and distributors. It has no recurring revenue stream, no customer-facing software layer, and no ownership of energy generation. Its success reflects disciplined component-level innovation—not ecosystem control.
9:24
GenmabJan van de Winkel · 1998Genmab is a platform biotech — not a drug developer — built around two licensed and proprietary antibody generation methods. Its value is in reducing discovery risk and time, not in owning clinical or commercial outcomes.
Up next in Business

Porsche

Ferdinand Porsche · 1931 · 10:55

Porsche didn’t start as a carmaker — it started as a government contractor that licensed its most famous design to someone else.

Play nextBack to Startups & venture
10:55